Pharma & Bio
Lifestyle
D&D Pharmatech Inc. Falls 18% Despite Clarification… ‘Expectations for K’s Obesity Treatment’ Shaken [Bio Spotlight]
D&D Pharmatech Inc.’s stock price fell sharply after it was confirmed that research and development on an obesity treatment candidate incorporating D&D Pharmatech Inc.(347850)’s technology had been su…
Technology
South Korea’s Regulatory Overhaul and U.S. Tariff Exemptions… SAMSUNG BIOLOGICS Among Direct Beneficiaries in the Spotlight
Regulatory changes in both South Korea and the United States are simultaneously shaking up the business environment for domestic Contract Development and Manufacturing Organizations (CDMOs). In South …
Lifestyle
Gil Young-jun, CEO of Huino: “Memocue Is Gaining Momentum Rapidly... Expecting to Turn a Profit Next Year”
Huino, which began as South Korea’s first information and communications technology (ICT) regulatory sandbox biotech venture, has overcome the high regulatory barriers in the remote monitoring market …
Technology
Inbosa in 2020: October Is the Final Showdown… Will Kolon TissueGene, Inc. Keep Pushing Forward Even If It Fails Again?
Kolon TissueGene, Inc.(950160) TG-C (formerly Invossa), a cell- and gene-based therapy for osteoarthritis, has once again reached a crossroads. After failing to meet the co-primary endpoints in its fi…
Technology
[Exclusive] Competition Heats Up to Win Over Hospitals… Concerns Over a ‘Chicken Game’ in the AI Patient Monitoring Market
“A competitor has offered a product we were supplying for 3.5 million won at around 1 million won. At that price, there’s virtually no way for us to compete.”Price competition to secure a foothold in …
Lifestyle
Broker Call Boosts Qurient; AbClon and L&C Bio Rebound on Rights Offering [K-Bio Pulse]
South Korea’s KOSDAQ market closed higher on Tuesday, supported by net buying from foreign and institutional investors, while most pharmaceutical and biotechnology stocks also gained. Qurient, AbClon,…
Lifestyle
20% Surge on a Single Report... Qurient Co., Ltd. and AbClon Inc. Soar, L&C BIO Reevaluated Following Rights Offering [Bio Spotlight]
The KOSDAQ market showed strength, driven by net buying from both foreign and institutional investors, and most stocks in the pharmaceutical and biotech sectors also closed higher. In particular, Quri…
Technology
Dot CEO Kim Ju-yoon, Who Has Secured Partnerships with Google, Apple, and Microsoft: "Expanding Surgical Robot Business... Currently Collaborating with Major Companies"
Dot, a social venture that commercialized the world’s first tactile display, is expanding its business beyond devices for the visually impaired into the surgical robotics market. Kim Ju-yun, CEO of Do…
KOSDAQ
DEEPNOID Inc. and Peptron, Inc. Rise… L&C BIO Weakens on Capital Increase [Bio Spotlight]
On the 3rd, the domestic pharmaceutical and biotech sector saw a tailwind thanks to the KOSDAQ’s strong performance. Buying pressure surged on the KOSDAQ that day, triggering the 16th “KOSDAQ Buy Side…
KOSDAQ
Deepnoid and Peptron Hit Daily Limit; L&C Bio Falls on Rights Offering [K-Bio Pulse]
South Korea’s pharmaceutical and biotechnology sector received a boost on Aug. 3 as the KOSDAQ market posted strong gains. Buying momentum intensified, triggering the 16th KOSDAQ buy-side circuit brea…